Welcome to our dedicated page for LAVA Therapeutics N.V. SEC filings (Ticker: LVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to historical SEC filings for LAVA Therapeutics N.V. (formerly Nasdaq: LVTX), a clinical-stage immuno-oncology company that developed bispecific gamma-delta T cell engagers using its Gammabody® platform. These documents trace both the company’s scientific focus and the corporate steps that led to its acquisition by XOMA Royalty Corporation and removal from the Nasdaq Global Select Market.
For investors and researchers, Forms 10-K, 10-Q and related reports (where applicable) offer detail on LAVA’s pipeline, including the internal candidate LAVA‑1266 for CD123+ hematologic malignancies and partnered programs JNJ‑89853413 with Johnson & Johnson and PF‑08046052 with Pfizer Inc. These filings typically describe the mechanism of action of LAVA’s bispecific gamma-delta T cell engagers, clinical trial status, risk factors, and collaboration economics.
The series of Form 8-K filings in 2025 is especially important for understanding LVTX as a former public company. They document entry into the Share Purchase Agreement with XOMA Royalty Corporation, amendments to the offer terms, the progress and results of the tender offer, the subsequent offering period, and the resulting change in control. Additional 8‑Ks describe shareholder votes at an extraordinary general meeting, LAVA’s notice of intent to voluntarily delist, Nasdaq’s suspension of trading and filing of Form 25 to remove LVTX from listing and registration, and LAVA’s stated intention to file Form 15 to terminate its reporting obligations.
Stock Titan’s platform surfaces these filings with AI-powered summaries that highlight key terms, conditions and implications, helping users quickly interpret complex documents such as the Share Purchase Agreement, CVR Agreement descriptions, and restructuring disclosures. You can review historical ownership and governance changes, transaction structures, and program-level information as reported directly to the SEC, while AI-generated insights point to the sections most relevant to LVTX’s transition from an independent Nasdaq-listed issuer to a majority-owned subsidiary of XOMA Royalty Corporation.
LAVA Therapeutics NV (LVTX) reported insider sales by affiliated reporting persons. On 10/08/2025, they sold 28,954 common shares at a weighted average price of $1.57 (range $1.56–$1.62). On 10/09/2025, they sold 48,169 shares at $1.56 (range $1.54–$1.59). On 10/10/2025, they sold 49,869 shares at $1.55 (range $1.53–$1.58).
Following these transactions, beneficial ownership reported as direct stood at 5,392,216, then 5,344,047, and finally 5,294,178 shares. The shares are held directly by Cooperatieve Gilde Healthcare IV U.A.; related entities Gilde Healthcare IV Management B.V. and Gilde Healthcare Holding B.V. disclaim beneficial ownership except to the extent of their pecuniary interests.
LAVA Therapeutics N.V. filed an amendment to its Schedule 14D-9 relating to the tender offer by XOMA Royalty Corporation to acquire all outstanding LAVA common shares. The amendment reports that, under the Purchase Agreement, the offer’s expiration has been extended from one minute after 11:59 p.m. Eastern Time on October 3, 2025 to one minute after 11:59 p.m. Eastern Time on October 17, 2025, with the possibility of further extensions in line with the agreement. The filing also adds a joint press release issued by XOMA Royalty Corporation and LAVA on October 2, 2025 as an exhibit.
LAVA Therapeutics N.V. furnished a Form 8-K reporting a material event and attached a Press Release dated September 30, 2025 as Exhibit 99.1 and a cover page interactive data file as Exhibit 104. The filing instructs investors they can obtain SEC filings free via the SEC website or from LAVA's investor relations page and references XOMA's investor relations as an additional source. The filing identifies Fred Powell, Chief Financial Officer, as a contact. The excerpt provided does not include the press release text or details about the underlying event; it lists exhibits and distribution instructions only.
Shay Capital LLC and Shay Capital Holdings LLC reported beneficial ownership of 2,596,403 common shares of LAVA Therapeutics NV, representing 9.9% of the class as of the filing. The filers list Delaware as their place of organization and give a principal business address at 280 Park Avenue, 5th Floor West, New York, NY 10017. The filing includes a certification that the securities were not acquired or held to change or influence control of the issuer and notes an attached Joint Filing Agreement. The filing identifies the issuer's principal executive office in Utrecht, Netherlands, and provides the CUSIP N51517105.
Amendment No. 2 to a Schedule 13D reports that certain Versant-affiliated reporting persons amended prior Schedule 13D disclosures for LAVA Therapeutics N.V. (Common Shares). The filing states that on September 19, 2025 Versant Venture Capital VI, L.P. sold 2,370,533 common shares at a weighted average price of $1.4014 per share for aggregate proceeds of approximately $3,322,064.95, and Versant Vantage I, L.P. sold 532,870 common shares at the same weighted average price for proceeds of approximately $746,764.02. As of that date the reporting persons ceased to beneficially own more than 5% of the issuer's outstanding common shares. The amendment incorporates prior Schedule 13D information not changed by this filing.
Versant-affiliated entities reported insider sales of LAVA Therapeutics (LVTX) common stock on 09/19/2025. The filing shows a total of 2,903,403 shares sold in two reported transactions: 2,370,533 shares (direct) and 532,870 shares (indirect) at a weighted average price of $1.4014 per share. Following these sales, the reporting person(s) report 0 shares beneficially owned for the directly held position. The sellers are investment entities affiliated with Versant (Versant Venture Capital VI, L.P.; Versant Vantage I, L.P.; and related GP entities). The form is signed by Max Eisenberg, Chief Operating Officer, on behalf of the reporting entities.
Versant-related entities report holdings and recent sales in LAVA Therapeutics (LVTX). Versant Venture Capital VI, L.P. beneficially owns 2,370,533 common shares, representing 9.0% of the class based on 26,305,295/395 shares outstanding reported as of August 8, 2025. Versant Vantage I, L.P. beneficially owns 532,870 shares, or 2.0%. The amendment states the reporting persons reserve the right to buy or sell additional shares or take other actions with respect to their positions.
The filing discloses open-market sales executed on September 16-18, 2025. Versant VI sold 307,707, 362,806, and 366,111 shares on those dates at weighted-average prices of $1.5332, $1.4892, and $1.4418, respectively. Vantage LP sold 192,293, 226,726, and 228,791 shares on the same dates at the same respective prices. The document provides aggregate proceeds for each tranche but does not state prior ownership levels before these sales.
Versant-related entities reported multiple sales of LAVA Therapeutics (LVTX) common stock on September 16-18, 2025. The filings show a series of dispositions: on 09/16/2025 two sell transactions of 307,707 and 192,293 shares at a weighted average price of $1.5332; on 09/17/2025 two sells of 362,806 and 226,726 shares at a weighted average price of $1.4892; and on 09/18/2025 two sells of 366,111 and 228,791 shares at a weighted average price of $1.4418. Following those transactions, Versant Venture Capital VI, L.P. held 3,099,450 shares (direct) and Versant Vantage I, L.P. held 988,387 shares (indirect) before/after as specified per line entries. Footnotes state the reported prices are weighted averages from multiple transactions within disclosed ranges and describe the related fund and GP ownership relationships.
LAVA Therapeutics' board and Special Committee concluded the proposed transaction offers the highest value reasonably obtainable under current circumstances. The Purchase Agreement provides a Cash Amount of $1.16–$1.24 per share,$1.10 per share. The board determined the company lacks a viable standalone business plan after asset reviews, workforce reductions, and wind-down of clinical trials, making dissolution the most likely alternative absent a sale. Contingent Value Rights (CVRs) may provide shareholders potential additional future payments, and the board viewed the deal as offering maximum capital return, no financial risks, and high deal certainty for shareholders.
Summary
LAVA Therapeutics N.V. (Nasdaq: LVTX) convened an Extraordinary General Meeting for September 30, 2025 to seek shareholder votes on board appointments, discharge of directors and a post-offer reorganization tied to an acquisition offer from XOMA Royalty Corporation. XOMA offered $1.16 per share plus up to $0.08 additional cash per share and one contingent value right (CVR) per share, subject to the Purchase Agreement and Offer to Purchase. The Board unanimously recommends shareholders accept the Offer and vote "FOR" the EGM proposals. If conditions are met, a Downstream Merger, a loan to New Topco and cancellation of New Topco class A shares are contemplated as part of the Post-Offer Reorganization.